Technology Highlights

There are two major advantages of Diabrid^® Technology:

• Technology enables to produce difficult biologics in high titers in E. Coli leading to their economical production at scale up level. 
• Specially designed genetically stable clones facilitate Quality Biologics APIs.

Diabrid^® Technology Spotlight

“Diabrid^® Technology” addresses two major problems in the Biologics and therapeutic peptide industry:

• Higher cost of biologics production.
• Large scale production of long therapeutic peptides is very difficult, if not impossible by chemical synthesis.

The key advantages of Biomultifold^® technology includes:

• Biomultifold^® provides an innovative and highly efficient process for the production.
• Biomultifold^® enables to achieve expression levels of multi-grams of therapeutic proteins per liter of fermentation.
• Cost effective system for manufacturing and scale up production.

Biomultifold^®- Technology Spotlight

• Achieve multi-grams level of production of therapeutic proteins per liter of fermentation. 
• Innovative process optimization that multiplies the production of biopharmaceuticals in E. Coli.
• Very high biomass development.
• Very high levels of product titers.
• No need to change your clone - Easy regulatory process.
• Improved economics / Lower production costs.
• Technology is ideal for a robust scale-up production process.
• Applicable for a wide range of biopharmaceuticals.
• Including its suitability for the production of fragment of monoclonal antibodies in E. Coli.

The key advantages of NobleCleav^® technology includes:

• Innovative technology developed by Paras Biopharmaceuticals Finland Oy successfully results in quality biopharmaceutical products with comparative biological activity of the product.  
• Platform enables new and innovative ways.
• Employing combined unique expertise to perform cleavage of proteins with a fusion partner.
• Increased specificity and activity of processing.
• Decreased wastage and therefore decreased.
• Production costs.

NobleCleav^® Technology Spotlight

• Cleavage generates authentic N and C- terminus.
• Optimum plasmid copy number.
• Includes vectors that are most suitable for E. Coli.
• Expression systems.
• Incorporates tightly controlled protein expression.
• Enables high expression yields, even for difficult and challenging proteins.
• Incorporates gene construct with Paras Propriety Partner PPP and spacers suitable for high expression.

The key advantage of In-situ Protein Folding Technology includes:

• The technology offers all of the cost benefits of expression in E. Coli rather than in eukaryotic systems, while at the same time retaining the high yields obtained in cytoplasmic expression.
• The biologics produced are of the highest quality and have maximal biological activity.

Oxidative Protein Folding Technology Spotlight

• Low cost production of biologics that contain disulfide bonds.
• Large scale production of biologically active eukaryotic proteins in the cytoplasm of E. Coli.
• Decreased production costs via high yield production in E. Coli.
• Reduced process development time as in vitro refolding optimization is not required.